Cerebral Infarction Drugs Market Size

  • Report ID: 3382
  • Published Date: Mar 15, 2023
  • Report Format: PDF, PPT

Cerebral Infarction Drugs Market Size

Cerebral Infarction Drugs Market size is estimated to surpass USD 12053 Million by the end of 2035, witnessing around 8% CAGR during the forecast period, i.e., 2023-2035. In the year 2022, the industry size of cerebral infarction drugs was USD 6553 Million. The growth of the market can be attributed to the increasing frequency of cerebrovascular disease, coupled with the surging prevalence of ischemic strokes throughout the world. For instance, the frequency of ischemic strokes increased to over 7.8 million new ischemic strokes by 2019, which denotes ischemic strokes accounted for more than 63% of all incident strokes worldwide. Further, the worldwide growing ratio of the geriatric population, along with an increase in hypertension rate is another significant factor anticipated to fuel the growth of the global cerebral infarction drugs market over the forecast period.

 In addition to these, factors that are believed to fuel the market growth of cerebral infarction drugs include the rise in population throughout the world as the increasing population has been affected by numerous types of disorders and cerebral infarction can affect any person of any age group. According to the World Bank report, in 2021, the total population of the world has expanded to 7.89 billion. Additionally, the growing awareness in people regarding the cerebrovascular disease, along with the surging investment in developing novel drugs is also estimated to spur market growth throughout the forecast period.

Get more information on this report: Request Free Sample PDF

Browse Key Market Insights with Data Illustration:

Author Credits:  Radhika Pawar

  • Report ID: 3382
  • Published Date: Mar 15, 2023
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

Worldwide growing prevalence of sedentary lifestyle, rising cases of arterial embolism, and rising ratio of clinical trials and their positive outcomes are the major factors driving the market growth.

The market is anticipated to attain a CAGR of 8% over the forecast period, i.e., 2023-2035.

Risk of side effects associated with the treatment, and low awareness among people in emerging nations regarding the cerebral infarction are estimated to be the growth hindering factors for the market expansion.

The market in the North American region is projected to hold the largest market share by the end of 2035 and provide more business opportunities in the future.

The major players in the market are Amgen Inc., Sanofi-aventis Groupe, Abbott Laboratories, Merck & Co., Inc., Boehringer Ingelheim International GmbH, Amneal Pharmaceuticals, Inc., Novartis AG, Pfizer Inc., and others.

The company profiles are selected based on the revenues generated from the product segment, the geographical presence of the company which determines the revenue generating capacity as well as the new products being launched into the market by the company.

The market is segmented by diagnosis, drug class, distribution channel, and by region.

The hospitals segment is anticipated to garner the largest market size by the end of 2035 and display significant growth opportunities.
Inquiry Before Buying Request Free Sample

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying